The Food and Drug Administration's Center for Drug Evaluation and Research has launched an outreach effort that seeks healthcare providers' help in identifying misleading prescription-drug advertising and marketing practices.
FDA program targets misleading ads
The effort, tagged the Bad Ad Program, is aimed at helping FDA officials identify misleading promotional activities targeted at providers, as well as consumer ads that downplay drug risks and effectiveness, according to a news release.
The agency said it will roll out the program in three phases. The first phase will engage healthcare providers attending selected medical conventions and partner with specific medical societies to distribute educational materials. The second and third phases will expand on those efforts and update the educational materials.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.